Sugi Predict

Sugi Predict / Compounds / SCHEMBL3335183

SCHEMBL3335183

SCHEMBL3335183

O=C([C@@H]1CCCN1)N1CCOCC1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 7/20 0.57
▸ DPP8 Q6V1X1 4/20 0.57
▸ DPP9 Q86TI2 4/20 0.57
▸ FAP Q12884 1/20 0.47
▸ DPP7 Q9UHL4 1/20 0.47
▸ PIK3CB P42338 5/20 0.47
▸ PIK3CD O00329 4/20 0.47
▸ PIK3CA P42336 4/20 0.47
▸ PIK3CG P48736 3/20 0.47
▸ TSHR P16473 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3335187 1.00 DPP4 (0.57) DPP4DPP8DPP9FAPDPP7
SCHEMBL3834001 1.00 DPP4 (0.57) DPP4DPP8DPP9FAPDPP7
SCHEMBL10326190 0.95 DPP4 (0.51) DPP4DPP8DPP9FAPDPP7
Ammonia Solution, Strong SCHEMBL26111130 0.93 DPP4 (0.50) DPP4DPP8DPP9FAPDPP7
Hydrochloric Acid SCHEMBL15264500 0.93 DPP4 (0.50) DPP4DPP8DPP9FAPDPP7
SCHEMBL11439644 0.87 DPP4 (0.66) DPP4DPP8DPP9FAPDPP7
SCHEMBL21552116 0.87 DPP4 (0.66) DPP4DPP8DPP9FAPDPP7
SCHEMBL488953 0.85 DPP4 (0.64) DPP4DPP8DPP9FAPDPP7
SCHEMBL3332865 0.85 DPP4 (0.64) DPP4DPP8DPP9FAPDPP7
SCHEMBL488954 0.85 DPP4 (0.64) DPP4DPP8DPP9FAPDPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133465-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2023-05-04 — — US disclosed
WO-2022182194-A1 MELANOCORTIN-4 RECEPTOR AGONIST 주식회사 엘지화학 2022-09-01 — — WO disclosed
CN-105143183-B 4 amino butyric acid derivatives of biaryl substituted and its production and use 上海翰森生物医药科技有限公司 2018-01-09 — — CN disclosed
CN-104230865-B 4 amino butyric acid derivatives of biaryl substituted and its production and use 上海翰森生物医药科技有限公司 2018-01-09 — — CN disclosed
CN-105130869-B A kind of synthetic method of the ketone of Entresto intermediates (S) 5 (carbonyl of biphenyl 4) pyrrolidines 2 曾伟 2017-12-26 — — CN disclosed
US-8669266-B2 Quinoline-carboxamide derivatives as P2Y12 antagonists SANOFI (FR) 2014-03-11 — — US disclosed
US-20120077711-A1 Novel Ligands and Libraries of Ligands SUNESIS PHARMACEUTICALS, INC. (US) 2012-03-29 — — US disclosed
US-20100135999-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-06-03 — — US disclosed
EP-2148871-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-02-03 — — EP disclosed
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 — — US disclosed
EP-2103619-A1 IMIDAZOTHIAZOLE DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-09-23 — — EP disclosed
WO-2008128647-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2008-10-30 — — WO disclosed
US-20070249682-A1 Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications ZHENG ZHONGLI 2007-10-25 — — US disclosed
US-20070249682-A1 Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications ZHENG ZHONGLI 2007-10-25 — — US disclosed
US-7173046-B2 CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications BIOGEN, INC. (US) 2007-02-06 — — US disclosed
US-7173046-B2 CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications BIOGEN, INC. (US) 2007-02-06 — — US disclosed
US-4636567-A CNS DISORDERS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1987-01-13 — — US disclosed
US-4610821-A CENTRAL NERVOUS SYSTEM, THYROTROPIN RELEASING HORMONE YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1986-09-09 — — US disclosed
US-4564609-A NERVOUS SYSTEM DISORDERS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1986-01-14 — — US disclosed
EP-0123444-A1 4-Substituted-2-azetidinone compound, process of producing the compounds, and medicaments containing the compounds YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1984-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133465-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS PSEN2, CLN6, PSEN1 DPP4 870/4885DPP8 848/4885DPP9 777/4885
US-20070249682-A1 Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications CD40, CD40LG, TNFSF11 DPP4 341/4885DPP8 777/4885DPP9 1030/4885
US-20100135999-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS P2RY12, P2RY1, P2RY2 DPP4 2699/4885DPP8 2973/4885DPP9 2264/4885
US-20090312310-A1 Imidazothiazole derivatives TP53, MDM2, TP53BP1 DPP4 2929/4885DPP8 3304/4885DPP9 3492/4885
US-20120077711-A1 Novel Ligands and Libraries of Ligands LSS, ABCG2, SELL DPP4 3178/4885DPP8 2940/4885DPP9 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.